Key R&D projects
Main focus of our research and development teams are new microRNA biomarkers – short non-coding RNAs that are involved in pathogenesis of many diseases, including cancer, cardiovascular or neurodegenerative diseases.
Biovendor R&D has recently obtained a license for the new Two-Tailed RT-qPCR technology, which is a modern tool for the analysis of short molecules of small interfering RNA molecules such as miRNA, piRNA, siRNA and others. This technology, originally developed by TATAA Biocenter company, enables both the qualitative determination of miRNA molecules and their quantification. Based on this platform, tests for the diagnostics of colorectal cancer and bladder cancer are being developed.